Measurable residual diseases in haematological malignancies: current applications and future direction
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia Research"
DOI: 10.1016/s0145-2126(19)30291-7
Abstract: Minimal/ measurable residual diseases represents an independent prognostic indicator for several haematological malignancies helping to predict clinical outcome and enables for further assessment of the effectiveness of treatment. The methods of detection of MRD has… read more here.
Keywords: residual diseases; current applications; measurable residual; haematological malignancies ... See more keywords
Imetelstat in myeloid malignancies: current data and future directions
Sign Up to like & getrecommendations! Published in 2025 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2025.2482721
Abstract: ABSTRACT Introduction Telomerase reactivation allows cancer cells to maintain telomere length and evade senescence, making it an appealing therapeutic target. Imetelstat, an antisense oligonucleotide, is the first clinically effective telomerase inhibitor approved by the FDA… read more here.
Keywords: current data; myeloid malignancies; data future; malignancies current ... See more keywords
Amino acids in hematologic malignancies: Current status and future perspective
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Nutrition"
DOI: 10.3389/fnut.2023.1113228
Abstract: In recent years, growing emphasis has been placed on amino acids and their role in hematologic malignancies. Cancer cell metabolism is altered during tumorigenesis and development to meet expanding energetic and biosynthetic demands. Amino acids… read more here.
Keywords: amino acids; acids hematologic; hematologic malignancies; malignancies current ... See more keywords